mRNA-based gene therapy suggests promising capability in novel vaccine improvement in opposition to infectious diseases and new therapeutics for a huge variety of indications and diseases, including most cancers. mRNA has a brief half-life of approximately 7 h, bare mRNA is relatively at risk of degradation by exonucleases and endonucleases. Therefore, the application of mRNA in most cancers therapy seriously relies upon on efficient delivery systems. New mRNA delivery systems should meet easy manufacturing and advanced biocompatibility. In terms of excessive transfection efficiency, protection, and low manufacturing cost, peptide-based delivery gives splendid promise. Cell-penetrating peptides (CPPs) are commonly 4–40 amino acids long and possess cationic or amphipathic motifs which can pass the cell membrane. They had been used to supply insoluble small molecule drugs, proteins, and nucleic acids to target tissues and cells, and features emerged as non-viral options to viral vectors. Along with other non-viral vector production for mRNA delivery, Seattle Genova also offers services for the peptide conjugate mRNA production. With the help of unique technology and experts, Seattle Genova has started the services for peptide conjugate RNA production.
Peptide-based mRNA delivery methods are gaining momentum because of the flexibility of peptide sequences. Arginine-rich cationic CPPs are acknowledged to promote cell internalization via hydrogen bonding and electrostatic interactions with the cell membrane surface through the guanidinium group of arginine. Amphipathic CPPs are also composed of cationic lysine and/or arginine residues with a fair distribution of hydrophobic amino acids, which include tryptophan, leucine, alanine, and valine. These peptides show off excessive transfection performance because of the sturdy hydrophobic interaction and the penetration into lipid bilayers in the cell membrane. The mRNA-containing nanoparticles were produced by simple electrostatic complexation between mRNA and CPPs containing cationic and amphipathic sequences.
A peptide conjugate mRNA product.
A complete work report.
Thank you for your interest in our Peptide Conjugated mRNA Production services. Please complete the form below and we will contact you shortly.
Fields indicated by an * are required.